Bain Capital Life Sciences led a $120m Series C round in Angitia Biopharmaceuticals.

Bain Capital Life Sciences, an investment firm focusing on pharmaceutical, biotechnology, medical device, diagnostic, and life science tool companies, led a $120m Series C round in Angitia Biopharmaceuticals, a clinical-stage biotechnology company, with participation from Janus Henderson, OrbiMed, 3H Health Investment, Yonghua Capital, Legend Capital, and Elikon Venture. “The broad support for Angitia in this financing validates the hard work of our team, the clinical progress of our programs, and the quality of our emerging data. We express gratitude to our investors, new and returning, for their support in our journey to provide novel and effective treatments for patients with musculoskeletal disease, and we look forward to continuing to execute on developing these valuable medicines,” David Ke, Angitia CEO.